Prostate Cancer
Conditions
Keywords
prostasomes,, prostate cancer,, biomarkers
Brief summary
Prostate cancer is the most frequently diagnosed cancer among men over 50 years old in Western societies, with an incidence that is steadily increasing in most countries. The current, most commonly used biomarker for prostate cancer is prostate specific antigen (PSA), which has well known limitations in accuracy and requires additional testing. However, prostate cancer cells secrete exosomes, also known as prostasomes, which are only detectable in the blood of prostate cancer patients. The presence of prostasomes in the blood is in itself a prostate cancer diagnosis. However, the assay that has been designed for the purification of prostasomes requires additional testing for evaluating its robustness and usefulness in the clinical setting. Additionally, the evaluation of the cargo of the purified prostasomes may provide more information on the nature of the prostate cancer, which may help develop a molecular assay for a prostate cancer liquid biopsy rather than a tissue biopsy. Therefore, the purpose of this study is two-fold: a validation phase where the purification of prostasomes will be tested on plasma collected from prostate cancer patients and a molecular testing phase where the contents of the purified prostasomes will be evaluated on their ability to determine the grade of the prostate tumors. We will collaborate with Dr. Masood Kamali-Moghaddam at the Uppsala University (Department of Immunology, Genetics and Pathology) for molecular assay processing.
Interventions
DIAGNOSTIC_TESTGenetic analysis for the detection of prostasomes
Whole blood will be collected and processed within 2 hours. Samples will be brought to Hackensack University Medical Center and will be centrifuged. The plasma samples will be tested for presence of prostasomes using the ExoPLA (Exosome in situ Proximity Ligation Assay) assay and the prostasomes will be purified for further miRNA sequencing.
Sponsors
Hackensack Meridian Health
Uppsala University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Male * With elevated PSA or patients with diagnosed prostate cancer * 18 years and older * Willingness to participate in the study and compliance with protocol requirements * Have not received any type of treatment for prostate cancer
Exclusion criteria
* Patients with confirmed or suspected prostate cancer that have already received any type of treatment * Patients with another primary cancer within the past five years of prostate cancer diagnosis. However, superficial skin cancers such as basal cell or squamous cell cancers would not exclude a patient.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| sensitivity of the prostasome purification methodology | through study completion - up to 24 months | true positive rate of the prostasomes purification methodology using the prostasome detection results for each of the patient specimens (cases and controls) |
| specificity of the prostasome purification methodology | through study completion - up to 24 months | true negative rate of the prostasomes purification methodology using the prostasome detection results for each of the patient specimens (cases and controls) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quantification of the miRNA expression profiles of the purified protostomes both before and after treatment (in patients cohort only) | through study completion - up to 24 months | identify the top 20 most frequently expressed miRNA markers and their level of expression in each of the case patient specimens |
| Time to disease progression(in patient cohort only) | Up to 24 months | — |
| Time to disease relapse (in patient cohort only) | Up to 24 months | — |
| Overall survival (in patient cohort only) | Up to 24 months | — |
Countries
United States
Outcome results
None listed